USC study shows immigrant adults with liver cancer have higher survival than those born in the U.S., regardless of ethnicity

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Immigrant adults with liver cancer in the U.S. have higher survival rates than people with the disease who were born in the U.S., according to research from the USC Norris Comprehensive Cancer Center.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Positive high-level results from the EMERALD-1 phase III trial showed Imfinzi (durvalumab) in combination with transarterial chemoembolization, or TACE, and bevacizumab demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival versus TACE alone in patients with hepatocellular carcinoma eligible for embolization. The trial continues to follow the secondary endpoint of overall survival.

Login